Glasgow based life sciences company EnteroBiotix has secured £19 million in new funding to accelerate the development of its microbiome based treatments, with a particular focus on addressing irritable bowel syndrome. The investment marks a significant step in the company’s mission to transform gastrointestinal care by targeting the root causes of disease rather than just managing symptoms.
Strong Investor Backing
The funding round was led by Thairm Bio and Scottish National Investment Bank, with participation from existing investors. With this latest raise, EnteroBiotix has now secured more than £65 million in total funding since its founding.
The new capital will support both clinical development and the expansion of the company’s broader research and manufacturing capabilities.
Advancing a Lead Therapy for IBS
A major focus of the funding will be the progression of EnteroBiotix’s lead candidate, EBX 102 02, into a Phase 2b clinical trial. The study is already underway and is expected to involve approximately 300 patients.
Topline results from the trial are anticipated in the second half of 2027. The therapy is designed to treat irritable bowel syndrome, a condition that affects a large number of people worldwide and remains an area of significant unmet medical need.
By targeting IBS at a biological level, the company aims to deliver more effective and lasting outcomes for patients.
A Different Approach to Microbiome Health
Founded in 2017 by James McIlroy, EnteroBiotix focuses on microbiome based therapeutics that go beyond traditional probiotic solutions. While conventional approaches often provide limited benefits, the company’s treatments are designed to restore the gut microbiome in a more comprehensive way.
This strategy reflects a growing understanding of the microbiome’s role in human health, particularly in relation to gastrointestinal conditions. By addressing underlying imbalances, EnteroBiotix aims to improve treatment outcomes and raise the standard of care.
Expanding Clinical and Research Capabilities
In addition to advancing its lead programme, the company will use the funding to develop its wider clinical pipeline. This includes exploring new therapeutic applications and continuing research into microbiome science.
EnteroBiotix is also investing in scaling its manufacturing capabilities to support future commercialisation. As demand for microbiome based therapies grows, the ability to produce treatments at scale will be critical.
Strategic Partnerships and Collaboration
The company has established collaborations with leading research institutions, including Imperial College London. These partnerships support ongoing research efforts and contribute to the development of new therapeutic approaches.
By working with academic and industry partners, EnteroBiotix is strengthening its position within the global biopharmaceutical landscape.
Addressing a Global Health Challenge
Irritable bowel syndrome is a widespread condition that can significantly impact quality of life. Despite its prevalence, treatment options remain limited, often focusing on symptom management rather than addressing underlying causes.
EnteroBiotix’s approach aims to change this by leveraging advances in microbiome science to develop more effective therapies. CEO and founder James McIlroy has emphasised the company’s goal of delivering meaningful outcomes for patients and improving standards of care in gastrointestinal health.
Looking Ahead
With fresh funding and ongoing clinical trials, EnteroBiotix is entering a critical phase of development. The results of its upcoming studies will play a key role in determining the future of its lead therapy and its broader pipeline.
As interest in microbiome based treatments continues to grow, the company is positioning itself at the forefront of this emerging field. By combining scientific innovation with clinical development, EnteroBiotix is working toward new solutions for some of the most challenging conditions in gastrointestinal medicine.
